Loading…

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019

Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by...

Full description

Saved in:
Bibliographic Details
Published in:Journal of patient experience 2022, Vol.9, p.23743735221105673-23743735221105673
Main Authors: Razonable, Raymund R, Ganesh, Ravindra, Bishop, Rachel K, Culbertson, Tracy L, Destro Borgen, Molly, Hedin, Michelle C, Hopkins, Laura H, Jackson, Tammy A, Larsen, Jennifer J, Matoush, Jennifer A, Moehnke, Darcie E, Olson, Shelly M, Peterson, Kellie M, Rosedahl, Jordan, Philpot, Lindsey M
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anti-spike monoclonal antibodies emerged as effective early treatment of high-risk individuals with mild-to-moderate COVID-19. Although their clinical and safety outcomes have been reported, patient perspectives of these experimental therapies have not been evaluated. In this survey participated by 644/2412 (26.7% response) individuals evaluated for anti-spike monoclonal antibody therapies, the majority of 523 patients who received the antibody infusion were very satisfied with their overall patient experience, the quality of care provided, and various aspects of medical care. They voiced satisfaction with the communication with providers before and during treatment, including education provided about monoclonal antibody treatment, the potential benefits and adverse effects, detailed instructions on the process of infusion, and safety protocols employed at the infusion facilities. Nearly a quarter (23.6%) of 121 patients who declined therapy indicated they would accept treatment should it be offered again. These patient perspectives may be used to guide healthcare facilities and providers in optimizing the care provided to high-risk outpatients with COVID-19.
ISSN:2374-3735
2374-3743
DOI:10.1177/23743735221105673